BRIEF published on 11/13/2025 at 14:50, 11 months 21 days ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
PRESS RELEASE published on 11/13/2025 at 14:45, 11 months 21 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 1 year ago Xenetic Biosciences annonce une offre d'actions de 4,5 millions de dollars Biopharmaceutique Offre D'actions Immuno-oncologie Biosciences Xénétiques Canaccord Genuity
BRIEF published on 10/10/2025 at 15:35, 1 year ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
PRESS RELEASE published on 10/10/2025 at 15:30, 1 year ago Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock Xenetic Biosciences, Inc. announces pricing of underwritten stock offering, aiming to raise $4.5 million for immuno-oncology technologies. Canaccord Genuity acts as bookrunner Xenetic Biosciences Stock Offering Immuno-oncology Technologies Canaccord Genuity S-3 Registration Statement
BRIEF published on 08/13/2025 at 14:05, 1 year 2 months ago Xenetic Biosciences publie ses résultats financiers du deuxième trimestre 2025 Résultats Financiers Biosciences Xénétiques T2 2025 Développement De La DNase I Élargissement Des Partenariats
BRIEF published on 08/13/2025 at 14:05, 1 year 2 months ago Xenetic Biosciences Reports Q2 2025 Financial Results Financial Results Xenetic Biosciences Q2 2025 DNase I Development Partnership Expansions
PRESS RELEASE published on 08/13/2025 at 14:00, 1 year 2 months ago Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q2 2025 results, expands partnership with The Scripps Research Institute for DNase I with CAR T-cell therapies and ends quarter with $4.8M cash Financial Results Xenetic Biosciences DNase I The Scripps Research Institute CAR T-cell Therapies
BRIEF published on 07/30/2025 at 15:05, 1 year 3 months ago Xenetic Biosciences collabore avec PeriNess pour une étude sur le lymphome Immuno-oncologie Étude Clinique Thérapie À La DNase I Cellule CAR-T Lymphome À Grandes Cellules B
BRIEF published on 07/30/2025 at 15:05, 1 year 3 months ago Xenetic Biosciences Collaborates with PeriNess for Lymphoma Study Clinical Study Immuno-oncology DNase I Therapy CAR T-cell Large B Cell Lymphoma
Published on 11/04/2026 at 23:10, 2 hours 19 minutes ago Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 2 hours 29 minutes ago Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 3 hours 14 minutes ago Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 3 hours 24 minutes ago Stabilis Solutions Announces Third Quarter 2026 Results
Published on 11/05/2026 at 00:02, 1 hour 27 minutes ago EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
Published on 11/04/2026 at 19:41, 5 hours 48 minutes ago EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 6 hours 4 minutes ago Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:43, 6 hours 46 minutes ago EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Published on 11/04/2026 at 18:05, 7 hours 24 minutes ago Redis Expands Redis Iris to Give AI Agents the Memory, Context, and Messaging They Need to get to Production
Published on 11/04/2026 at 18:00, 7 hours 29 minutes ago The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 18:00, 7 hours 29 minutes ago L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Published on 11/04/2026 at 17:44, 7 hours 45 minutes ago Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026
